This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.
Patients with non-small cell lung cancer diagnosed by histopathology or cytopathology.
Presence of bone metastases.
EGFR/ALK gene wild type.
No prior treatment with PD-1 inhibitors (combination or monotherapy)
Unable to complete the baseline assessment form
Combination of other serious illnesses, including uncontrolled active infection, severe electrolyte disturbances, and significant bleeding tendencies.
Pregnant or lactating women.
Combined autoimmune diseases, hematologic disorders, or long-term use of hormones or immunosuppressive drugs.